Gentium Investors Sue Over $1B Jazz Pharma Deal
By Sindhu Sundar ( January 16, 2014, 5:49 PM EST) -- Italy-based biopharmaceutical firm Gentium SpA and its suitor Jazz Pharmaceuticals Public Limited Co. were hit with a proposed class action in New York federal court Wednesday by Gentium shareholders claiming the $1 billion that Jazz is offering for the planned acquisition is "unfair."...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.